West Family Investments Inc. Buys 630 Shares of Cencora, Inc. $COR

West Family Investments Inc. increased its stake in Cencora, Inc. (NYSE:COR) by 20.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,758 shares of the company’s stock after purchasing an additional 630 shares during the quarter. West Family Investments Inc.’s holdings in Cencora were worth $1,127,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Atlantic Edge Private Wealth Management LLC grew its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Cencora in the first quarter valued at approximately $28,000. Vermillion & White Wealth Management Group LLC grew its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after acquiring an additional 43 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after acquiring an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the 2nd quarter worth approximately $61,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $368.93 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $71.53 billion, a PE ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The business’s 50-day moving average price is $335.71 and its 200-day moving average price is $307.44. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the company posted $3.34 EPS. Cencora’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 30.19%.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares in the company, valued at $24,105,113.44. This represents a 7.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,640 shares of company stock valued at $14,099,338 over the last three months. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday. Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Tuesday. Finally, TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.